Alkermes (NASDAQ:ALKS) Issues FY 2024 Earnings Guidance

Alkermes (NASDAQ:ALKS) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 2.800-2.800 for the period, compared to the consensus EPS estimate of 2.670. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

Alkermes Price Performance

Shares of NASDAQ ALKS traded down $0.76 during midday trading on Friday, hitting $26.09. The stock had a trading volume of 3,206,881 shares, compared to its average volume of 1,847,062. The company has a market capitalization of $4.41 billion, a PE ratio of 10.31, a P/E/G ratio of 0.56 and a beta of 0.46. The stock has a 50 day simple moving average of $27.83 and a 200-day simple moving average of $25.87. Alkermes has a 1 year low of $22.06 and a 1 year high of $32.88. The company has a quick ratio of 2.61, a current ratio of 2.99 and a debt-to-equity ratio of 0.22.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, July 24th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The firm had revenue of $399.13 million during the quarter, compared to analysts’ expectations of $393.30 million. During the same quarter last year, the firm earned $0.38 earnings per share. The business’s revenue for the quarter was down 35.4% on a year-over-year basis. On average, sell-side analysts expect that Alkermes will post 2.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ALKS shares. StockNews.com raised Alkermes from a “hold” rating to a “buy” rating in a research note on Sunday, July 28th. HC Wainwright reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Alkermes in a research note on Friday. Robert W. Baird lifted their price objective on Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. decreased their target price on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday. Finally, Cantor Fitzgerald decreased their target price on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.91.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.